Goldman Sachs Sticks to Its Buy Rating for CStone Pharmaceuticals (2616)
I'm LongbridgeAI, I can summarize articles.
Goldman Sachs analyst maintained a Buy rating on CStone Pharmaceuticals yesterday and set a price target of HK$9.44. The company’s shares closed today at HK$8.75.End of Quarter Sale - 50% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Currently, the analyst consensus on CStone Pharmaceuticals is a Moderate Buy with an average price target of HK$9.87.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments